COVID-19：甲磺酸萘法莫他的治疗作用：东京大学证实
新型冠状病毒肺炎（COVID-19）：新冠肺炎（COVID-19）：COVID-19：
2020/7/8 05:00
东京大学医院：土井副教授
对“患有肺炎并需要在重症监护病房（ICU）进行治疗的重症COVID-19患者”进行了临床研究。
组合使用了COVID-19治疗候选药物“甲磺酸萘法莫他”和“依维拉韦（商品名：Avigan）”。
进行临床试验：
11例患者中有10例症状恢复。
该方法适用于11月（36岁至75岁）从4月6日至21日住院的11例患者（男10例，女1例）。
遵守临床过程。
甲磺酸萘法莫他：
每1个小时每公斤体重服用0.2毫克的甲磺酸萘法莫他，持续约2周。
法维皮拉大厦：
在第一天每天以3600 mg服用法维拉韦，从第二天开始以1600 mg服用约2周。
医疗状况恢复状况：
在10个人中看到症状恢复。
在康复的患者中，
有7位患者使用了呼吸机。
七分之三的人需要心肺支持系统（ECMO）。
但是，大约16天后就不需要使用呼吸机了。
具体临床研究规模：
观察综合作用的具体临床研究是：
从五月开始，东京大学医院
它在日本的6家工厂开始，到5月底在8家工厂举行。
结果发表在重症医学期刊的电子版中。
两种候选药物在病毒生长过程中具有不同的作用部位。
因此，期望组合使用的效果。
日刊工业新闻
https://www.nikkan.co.jp/articles/view/00563690
Identification of an existing Japanese pancreatitis drug, Nafamostat, which is expected to prevent the transmission of new coronavirus infection (COVID-19)
March 23, 2020
Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis,
may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19).
The University of Tokyo announced these new findings on March 18, 2020.
According to the new research,
Nafamostat
can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus SARS-CoV-2.
Nafamostat
can inhibit the membrane fusion at a concentration less than one-tenth that of Camostat mesylate (brand name: Foypan), which was recently identified by a German group as an inhibitor of SARS-CoV-2 infection (Reference 1).
Both Nafamostat and Camostat
were developed in Japan as treatments for pancreatitis and some other diseases.
These drugs
have been prescribed in Japan for many years and have adequate clinical data with regard to safety.
THE INSTITUTE OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYO
https://www.ims.u-tokyo.ac.jp/imsut/en/about/press/page_00002.html